search
Back to results

Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)

Primary Purpose

Colorectal Cancer

Status
Recruiting
Phase
Phase 3
Locations
Germany
Study Type
Interventional
Intervention
mFOLFOX6
mFOLFOXIRI
Sponsored by
Dominik Paul Modest
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Colorectal Cancer focused on measuring Colorectal Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patient's signed informed consent.
  2. Patient's age ≥18 years at the time of signing the informed consent.
  3. Histologically confirmed adenocarcinoma of the colon or rectum.
  4. Resected (R0 or R1) and/or effectively treated metastases (all techniques allowed) of colorectal cancer within 3-10 weeks before randomization AND resected primary tumor (synchronous or metachronous).
  5. Absence of significant active wound healing complications (if applicable) prior to randomization. Resolved wound healing complications after resection/ablation are acceptable for inclusion into the trial.
  6. No radiographic evidence of active metastatic disease at study entry in a CT and/or MRI scan not older than 8 weeks. Pre-surgery/ablation images are eligible for the study if all lesions have been addressed in the interval.
  7. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
  8. Adequate bone marrow, hepatic and renal organ function, defined by the following laboratory test results:

    • Absolute neutrophil count ≥ 1.5E+9/L (1500/µL)
    • Hemoglobin ≥ 80 g/L (8 g/dL)
    • Platelet count ≥ 100E+9/L (100000/µL) without transfusion
    • Total serum bilirubin of ≤ 1.5 x upper limit of normal (ULN)
    • Aspartate aminotransferase (AST/GOT) ≤ 3.0 × ULN.
    • Calculated glomerular filtration rate (GFR) according to Cockcroft-Gault formula or according to MDRD ≥ 50 mL/min or serum creatinine ≤ 1.5 x ULN
  9. Patients without anticoagulation need to present with an international normalized ratio (INR) < 1.5 x ULN and prothrombin time (PTT) < 1.5 x ULN. Patient with prophylactic or therapeutic anticoagulation are allowed into the trial.
  10. Proficient fluorouracil metabolism as defined:

    1. Prior treatment with 5-FU or capecitabine without unusual toxicity or
    2. If tested, normal dihydropyrimidine dehydrogenase (DPD) deficiency test according to the standard of the study site or
    3. If tested, in patients with DPD deficiency test with a Clinical Pharmacogenetics Implementation Consortium (CPIC) activity score of 1.0-1.5 fluoropyrimidine dosage should be reduced by 50%
  11. For women of childbearing potential (WOCBP): negative pregnancy test within 14 days before randomization and agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for at least 6 months after the last dose of study treatment.

A woman is considered to be of childbearing potential if she is post-menarcheal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male partner's sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.

For men: With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for 6 months after the last dose of study treatment. Men must refrain from donating sperm during this same period.

Exclusion Criteria:

  1. Treatment of metastases greater than 3 cm with radio-frequency/microwave ablation within 24 months prior to study entry if applicable.
  2. Treatment of metastases greater than 5 cm with radiation (stereotactic/ brachytherapy) within 24 months prior to study entry if applicable.
  3. Previous chemotherapy for metastatic or localized disease with > 6 cycles of FOLFOX (or FOLFOXIRI) or > 4 cycles of Capecitabine/Oxaliplatin (CAPOX)/XELOX.
  4. New York Heart Association Class III or greater heart failure by clinical judgement.
  5. Myocardial infarction within 6 months prior to randomization; percutaneous transluminal coronary angioplasty (PTCA) with or without stenting within 6 months prior to randomization.
  6. Unstable angina pectoris.
  7. Unstable cardiac arrhythmia > grade 2 NCI CTCAE despite anti-arrhythmic therapy.
  8. Ongoing toxicities > grade 2 NCI CTCAE, in particular peripheral neuropathy.
  9. Active uncontrolled infection by investigator's perspective.
  10. Severe chronic non-healing wounds, ulcerous lesions or untreated bone fracture.
  11. Known hypersensitivity to 5-FU, leucovorin, irinotecan or oxaliplatin or to any of the other excipients listed in section 6.1 of the corresponding Summary of Product Characteristics (SmPC).
  12. Bone marrow depression after radio- or chemotherapy.
  13. Severe kidney dysfunction (creatinine clearance < 30 ml/min) or changes in blood count.
  14. Recent or concomitant treatment with brivudine.
  15. Peripheral sensitive neuropathy with functional impairment (> grade 1 acc. to CTCAE version 5.0 (see appendix)).
  16. Inflammatory bowel disease and/or bowel obstruction.
  17. Simultaneous application of Johannis herbs preparations.
  18. Pernicious or other megaloblastic anaemia caused by vitamin B12 deficiency.
  19. If tested, DPD deficiency test with a CPIC activity score <1.
  20. Major surgical procedure, open biopsy, or significant traumatic injury within 21 days prior to randomization, or abdominal surgery, abdominal interventions or significant abdominal traumatic injury within 21 days prior to randomization or anticipation of need for major surgical procedure during the course of the study or non-recovery from side effects of any such procedure.
  21. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications.
  22. Medical history of malignant disease other than metastatic colorectal cancer (mCRC) with the following exceptions:

    • patients who have been disease-free for at least three years before randomization
    • patients with adequately treated and completely resected basal cell or squamous cell skin cancer, in situ cervical, breast or prostate cancer, stage I uterine cancer
    • patients with any treated or untreated malignant disease that is associated with a 5-year survival prognosis of ≥ 90% and does not require active therapy
  23. Known alcohol or drug abuse.
  24. Pregnant or breastfeeding females.
  25. Participation in a clinical trial or experimental drug treatment within 28 days prior to potential inclusion in the clinical trial or within a period of 5 half-lives of the substances administered in a clinical trial or during an experimental drug treatment prior to potential inclusion in the clinical trial, depending on which period is longest, or simultaneous participation in another clinical trial while taking part in this clinical trial.
  26. Patients depended on Sponsor, investigator or study site.
  27. Suspected SARS-CoV-2 infection with or without symptoms (evaluation according to local policy in respective center with respect to actual status of pandemic and with reference to the policy that would apply to patients with similar therapy outside the trial). This may include assessment of vaccination status, anamnesis, physical examination and potentially antigen and/or PCR testing.
  28. Patient committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.
  29. Limited legal capacity.

Sites / Locations

  • Klinikum St. Marien AmbergRecruiting
  • Helios Klinikum Bad SaarowRecruiting
  • Klinikum BayreuthRecruiting
  • Charité Universitätsmedizin BerlinRecruiting
  • Helios Klinikum Emil von BehringRecruiting
  • MVZ Onkologischer Schwerpunkt am Oskar-Helene-HeimRecruiting
  • Vivantes Klinikum am Urban BerlinRecruiting
  • Vivantes Klinikum Spandau BerlinRecruiting
  • St. Josef-Hospital BochumRecruiting
  • Johanniterkrankenhaus BonnRecruiting
  • Diakonie-Krankenhaus BremenRecruiting
  • Klinikum ChemnitzRecruiting
  • Klinikum DarmstadtRecruiting
  • DONAUISAR Klinikum DeggendorfRecruiting
  • Städtisches Klinikum DessauRecruiting
  • Onkologische-Gemeinschaftspraxis DresdenRecruiting
  • Onkozentrum DresdenRecruiting
  • Universitätsklinikum DüsseldorfRecruiting
  • Kliniken Essen-MitteRecruiting
  • Universitätsklinikum EssenRecruiting
  • KHNW FrankfurtRecruiting
  • Markus-Krankenhaus FrankfurtRecruiting
  • Universitätsklinikum FrankfurtRecruiting
  • Universitätsklinikum FreiburgRecruiting
  • Gemeinschaftspraxis internistische Onkologie FürthRecruiting
  • Niels-Stensen Kliniken GeorgsmarienhütteRecruiting
  • Praxis Hämatologie Onkologie GießenRecruiting
  • Universitätsmedizin GöttingenRecruiting
  • Universitätsklinikum HalleRecruiting
  • Universitätsklinikum Hamburg-EppendorfRecruiting
  • Medizinische Hochschule HannoverRecruiting
  • St. Anna Hospital HerneRecruiting
  • Universitätsklinikum des SaarlandesRecruiting
  • Klinikum Ingolstadt GmbHRecruiting
  • Universitätsklinikum JenaRecruiting
  • Kliniken der Satdt Köln
  • Klinikum LandshutRecruiting
  • VK&K Studien LandshutRecruiting
  • Studienzentrum UnterEms LeerRecruiting
  • Universitätsklinikum LeipzigRecruiting
  • Klinikum LeverkusenRecruiting
  • Klinikum LippeRecruiting
  • Klinikum LudwigsburgRecruiting
  • Klinikum MagdeburgRecruiting
  • Universitätsmedizin MainzRecruiting
  • OnkoNet Marburg GmbHRecruiting
  • Philipps-Universität MarburgRecruiting
  • Johannes Wesling Klinikum MindenRecruiting
  • Kliniken Maria Hilf MönchengladbachRecruiting
  • Klinikum der Universität MünchenRecruiting
  • Klinikum rechts der Isar TU MünchenRecruiting
  • München Klinik BogenhausenRecruiting
  • München Klinik NeuperlachRecruiting
  • Gemeinschaftspraxis MünsterRecruiting
  • Universitätsklinikum MünsterRecruiting
  • Friedrich-Ebert-Krankenhaus NeumünsterRecruiting
  • Lukaskrankenhaus NeussRecruiting
  • Klinikum NürnbergRecruiting
  • Pi.Tri-Studien GmbH OffenburgRecruiting
  • Klinikum PassauRecruiting
  • Schwerpunktpraxis PenzbergRecruiting
  • Ernst von Bergmann Klinikum PotsdamRecruiting
  • Studienzentrum Onkologie RavensburgRecruiting
  • Krankenhaus Barmherzige Brüder RegensburgRecruiting
  • Universitätsklinikum RegensburgRecruiting
  • Kreiskliniken ReutlingenRecruiting
  • Mathias Spital RheineRecruiting
  • RoMed Klinikum RosenheimRecruiting
  • Universitätsmedizin RostockRecruiting
  • DIAK Klinikum Schwäbisch HallRecruiting
  • Marienkrankenhaus SiegenRecruiting
  • Klinikum StuttgartRecruiting
  • Marienhospital StuttgartRecruiting
  • Krankenhaus der Barmherzigen Brüder TrierRecruiting
  • Universitätsklinikum UlmRecruiting
  • Klinikum WetzlarRecruiting
  • Onkologisches Zentrum Wolfsburg-HelmstedtRecruiting
  • Petrus-Krankenhaus WuppertalRecruiting
  • Gemeinschaftspraxis WürzburgRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Treatment

Control

Arm Description

Active treatment with mFOLFOXIRI or mFOLFOX6 q2w up to six months followed by structured Follow-up for up to five years after randomization

Structured Follow-up for up to five years after randomization

Outcomes

Primary Outcome Measures

Progression-free survival (PFS) time
time from randomization to death or evidence of disease relapse/progression (whatever occurs first)

Secondary Outcome Measures

Overall survival (OS)
time from randomization to the date of death of any cause
Control ol lesions
Local or distant control of lesions according to ablative technique (surgery vs. ablation vs. radiation)
(Serious) Adverse Events
Type, incidence, severity, and causal relationship to active chemotherapy of non-serious adverse events and serious adverse events (severity evaluated according to CTCAE version 5.0)
Quality of life (QoL)
Quality of life (QoL) as assessed with the QoL questionnaire EQ-5D-5L

Full Information

First Posted
August 6, 2021
Last Updated
July 20, 2023
Sponsor
Dominik Paul Modest
Collaborators
German Research Foundation, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
search

1. Study Identification

Unique Protocol Identification Number
NCT05008809
Brief Title
Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)
Official Title
Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer Prospective, Randomized, Open, Multicenter Phase III Trial to Investigate the Efficacy of Active Post-resection/Ablation Therapy in Patients With Metastatic Colorectal Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 6, 2021 (Actual)
Primary Completion Date
November 2027 (Anticipated)
Study Completion Date
November 2030 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Dominik Paul Modest
Collaborators
German Research Foundation, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is an open-label, randomized, controlled, multicenter, phase III study with two parallel arms. Patients with metastatic colorectal cancer after definite interventional therapy of all lesions are randomized in a 2:1 fashion (favoring active therapy) to investigate the efficacy, patient reported quality of life and safety of mFOLFOXIRI/mFOLFOX-6 as additive treatment (Arm A) versus active follow-up/surveillance (Arm B).
Detailed Description
The trial will consist of both a clinical and translational part. During the study, re-assessments (radiologic assessment, blood and QoL) will be conducted for all trial subject of the trial every 3 months. Tumor biopsies will be collected at screening (baseline sample) and in case of relapse of disease if a new tumor sample is obtained. The objective of the re-assessments is detection of relapse either radiologically or within the translational material (blood samples with ctDNA dynamics and tumor - if available from relapses). CT scans of thorax/abdomen and/or MRI scans will be performed every 3 months within the 2 years after randomization. After the first two relapse-free years, intervals should be stretched to 6 months in the third and following years after study start. Structured follow-up for up to 60 months after randomization should be maintained for both arms. Patients in Arm A receive additive study drug intervention (mFOLFOXIRI or mFOLFOX-6) for up to six months (12 cycles) after randomization with additional clinical and safety assessments.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Cancer
Keywords
Colorectal Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
open-label, randomized, controlled, multicenter, phase III study with two parallel arms
Masking
None (Open Label)
Allocation
Randomized
Enrollment
507 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Treatment
Arm Type
Experimental
Arm Description
Active treatment with mFOLFOXIRI or mFOLFOX6 q2w up to six months followed by structured Follow-up for up to five years after randomization
Arm Title
Control
Arm Type
No Intervention
Arm Description
Structured Follow-up for up to five years after randomization
Intervention Type
Drug
Intervention Name(s)
mFOLFOX6
Other Intervention Name(s)
Leucovorin, Oxaliplatin, 5-fluorouracil (FU)
Intervention Description
Oxaliplatin: 85 mg/m², 2h IV infusion on d1 Leucovorin: 400 mg/m², 1-2 h IV infusion on d1 5-FU: (optional: 400 mg/m² bolus, 2-5 min IV infusion), 2400 mg/m², 46 h IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles are administered.
Intervention Type
Drug
Intervention Name(s)
mFOLFOXIRI
Other Intervention Name(s)
Leucovorin, Oxaliplatin, 5-FU, Irinotecan
Intervention Description
Oxaliplatin: 85 mg/m², 2h IV infusion on d1 Irinotecan: 150 mg/m², 90 min IV infusion on d1 Leucovorin: 400 mg/m², 1-2 h IV infusion on d1 5-FU: 2400 mg/m², 46 h IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles are administered.
Primary Outcome Measure Information:
Title
Progression-free survival (PFS) time
Description
time from randomization to death or evidence of disease relapse/progression (whatever occurs first)
Time Frame
24 months
Secondary Outcome Measure Information:
Title
Overall survival (OS)
Description
time from randomization to the date of death of any cause
Time Frame
at least 5 years after randomization
Title
Control ol lesions
Description
Local or distant control of lesions according to ablative technique (surgery vs. ablation vs. radiation)
Time Frame
up to 5 years after randomization
Title
(Serious) Adverse Events
Description
Type, incidence, severity, and causal relationship to active chemotherapy of non-serious adverse events and serious adverse events (severity evaluated according to CTCAE version 5.0)
Time Frame
up to 2 years after randomization
Title
Quality of life (QoL)
Description
Quality of life (QoL) as assessed with the QoL questionnaire EQ-5D-5L
Time Frame
up to 5 years after randomization

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient's signed informed consent. Patient's age ≥18 years at the time of signing the informed consent. Histologically confirmed adenocarcinoma of the colon or rectum. Resected (R0 or R1) and/or effectively treated metastases (all techniques allowed) of colorectal cancer within 3-10 weeks before randomization (earlier randomisation allowed if at least 3 weeks interval between intervention and treatment start is guaranteed) AND resected primary tumor (synchronous or metachronous). In cases of synchronous metastases the interval of 3-10 weeks might be calculated following the removal of the primary tumor if this intervention was the last to address all tumor lesions. Absence of significant active wound healing complications (if applicable) at randomization. Resolved wound healing complications after resection/ablation are acceptable for inclusion into the trial. No radiographic evidence of active metastatic disease at study entry in a CT and/or MRI scan not older than 10 weeks prior randomization. Pre-surgery/ablation images are eligible for the study if all lesions have been addressed in the interval ECOG performance status 0-2. Adequate bone marrow, hepatic and renal organ function, defined by the following laboratory test results: Absolute neutrophil count ≥ 1.5 x 109/L (1500/µL) Hemoglobin ≥ 80 g/L (8 g/dL) Platelet count ≥ 100 x109/L (100000/µL) without transfusion Total serum bilirubin of ≤ 1.5 x upper limit of normal (ULN) Aspartate aminotransferase (AST/GOT) ≤ 3.0 × ULN. Calculated glomerular filtration rate (GFR) according to Cockcroft-Gault formula or according to MDRD ≥ 50 mL/min or serum creatinine ≤ 1.5 x ULN Patients without anticoagulation need to present with an INR < 1.5 x ULN and PTT < 1.5 x ULN. Patient with prophylactic or therapeutic anticoagulation are allowed into the trial. Proficient fluorouracil metabolism as defined: Prior treatment with 5-FU or capecitabine without unusual toxicity or If tested, normal DPD deficiency test according to the standard of the study site or If tested, in patients with DPD deficiency test with a CPIC activity score of 1.0-1.5 fluoropyrimidine dosage should be reduced by 50% For women of childbearing potential (WOCBP): negative pregnancy test within 14 days before randomization and agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for at least 6 months after the last dose of study treatment. A woman is considered to be of childbearing potential if she is post-menarcheal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male partner's sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. For men: With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for 6 months after the last dose of study treatment. Men must refrain from donating sperm during this same period. With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for 6 months after the last dose of study medication to avoid exposing the embryo. Exclusion Criteria: Treatment of metastases greater than 3 cm with radio-frequency/microwave ablation within 24 months prior to study entry if applicable. Treatment of metastases greater than 5 cm with radiation (stereotactic/ brachytherapy) within 24 months prior to study entry if applicable. Previous chemotherapy at any time for metastatic or localized disease with > 6 cycles of FOLFOX (or FOLFOXIRI) or > 4 cycles of CAPOX/XELOX. Any other pretreatment is permitted, including unlimited use of antibodies, fluoropyrimidines and irinotecan. New York Heart Association Class III or greater heart failure by clinical judgement. Myocardial infarction within 6 months prior to randomization; percutaneous transluminal coronary angioplasty (PTCA) with or without stenting within 6 months prior to randomization. Unstable angina pectoris. Unstable cardiac arrhythmia > grade 2 NCI CTCAE despite anti-arrhythmic therapy. Ongoing toxicities > grade 2 NCI CTCAE Active uncontrolled infection by investigator's perspective. Severe chronic non-healing wounds, ulcerous lesions or untreated bone fracture. Known hypersensitivity to 5-FU, leucovorin, irinotecan or oxaliplatin or to any of the other excipients listed in section 6.1 of the corresponding SmPC. Recent or concomitant treatment with brivudine. Peripheral sensitive neuropathy with functional impairment (> grade 1 acc. to CTCAE version 5.0 (see appendix 2)). Inflammatory bowel disease and/or bowel obstruction. Simultaneous application of Johannis herbs preparations. Pernicious or other megaloblastic anaemia caused by vitamin B12 deficiency. Major surgical procedure, open biopsy, or significant traumatic injury within 21 days prior to randomization or at least to intended treatment start or anticipation of need for major surgical procedure during the course of the study or non-recovery from side effects of any such procedure. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications. Medical history of malignant disease other than mCRC with the following exceptions: patients who have been disease-free for at least three years before randomization patients with adequately treated and completely resected basal cell or squamous cell skin cancer, in situ cervical, breast or prostate cancer, stage I uterine cancer patients with any treated or untreated malignant disease that is associated with a 5-year survival prognosis of ≥ 90% and does not require active therapy Known alcohol or drug abuse. Pregnant or breastfeeding females. Participation in a clinical trial or experimental drug treatment within 28 days prior to potential inclusion in the clinical trial or within a period of 5 half-lives of the substances administered in a clinical trial or during an experimental drug treatment prior to potential inclusion in the clinical trial, depending on which period is longest, or simultaneous participation in another clinical trial while taking part in this clinical trial. Patients depended on Sponsor, investigator or study site. Suspected SARS-CoV-2 infection with or without symptoms (evaluation according to local policy in respective center with respect to actual status of pandemic and with reference to the policy that would apply to patients with similar therapy outside the trial). This may include assessment of vaccination status, anamnesis, physical examination and potentially antigen and/or PCR testing. Patient committed to an institution by virtue of an order issued either by the judicial or the administrative authorities. Limited legal capacity. Concomitant administration of strong CYP3A4 and/or UGT1A1 inducers (e.g. Rifampicin, Carbamazepin, Phenobarbital, Phenytoin or Apalutamid). Planned inoculation/vaccination with a live vaccine during treatment with Oxaliplatin and/or Irinotecan, and until 6 months after treatment with Irinotecan.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dominik Modest, Prof. Dr.
Phone
+49 30 450
Ext
553222
Email
dominik.modest@charite.de
First Name & Middle Initial & Last Name or Official Title & Degree
Daniel Müller, Dr.
Phone
+49 69 7601
Ext
125
Email
mueller.daniel@ikf-khnw.de
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dominik Modest, Prof. Dr.
Organizational Affiliation
Charite University, Berlin, Germany
Official's Role
Principal Investigator
Facility Information:
Facility Name
Klinikum St. Marien Amberg
City
Amberg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ludwig Fischer von Weikersthal, Dr.
Facility Name
Helios Klinikum Bad Saarow
City
Bad Saarow
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Daniel Pink, Dr.
Facility Name
Klinikum Bayreuth
City
Bayreuth
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexander Kiani, Prof. Dr.
Facility Name
Charité Universitätsmedizin Berlin
City
Berlin
ZIP/Postal Code
13353
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dominik Modest, Prof. Dr.
Phone
+49 30 450
Ext
553222
Email
dominik.modest@charite.de
Facility Name
Helios Klinikum Emil von Behring
City
Berlin
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Börge Arndt, Dr.
Facility Name
MVZ Onkologischer Schwerpunkt am Oskar-Helene-Heim
City
Berlin
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Markus Schuler, Dr.
Facility Name
Vivantes Klinikum am Urban Berlin
City
Berlin
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Annette Dieing, Dr.
Facility Name
Vivantes Klinikum Spandau Berlin
City
Berlin
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jörg-Christian Rath, Dr.
Facility Name
St. Josef-Hospital Bochum
City
Bochum
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anke Reinacher-Schick, Prof. Dr.
Facility Name
Johanniterkrankenhaus Bonn
City
Bonn
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yon-Dschun Ko, Prof. Dr.
Facility Name
Diakonie-Krankenhaus Bremen
City
Bremen
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ralf Ulrich Trappe, Prof. Dr.
Facility Name
Klinikum Chemnitz
City
Chemnitz
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hagen Rudolph, Dr.
Facility Name
Klinikum Darmstadt
City
Darmstadt
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carl Schimanski, Prof. Dr.
Facility Name
DONAUISAR Klinikum Deggendorf
City
Deggendorf
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicolas Graf, PD Dr.
Facility Name
Städtisches Klinikum Dessau
City
Dessau
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gerhard Behre, Prof. Dr.
Facility Name
Onkologische-Gemeinschaftspraxis Dresden
City
Dresden
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lutz Jacobasch, Dr.
Facility Name
Onkozentrum Dresden
City
Dresden
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Steffen Dörfel
Facility Name
Universitätsklinikum Düsseldorf
City
Düsseldorf
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christoph Roderburg, Prof. Dr.
Facility Name
Kliniken Essen-Mitte
City
Essen
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Stahl, Prof. Dr.
Facility Name
Universitätsklinikum Essen
City
Essen
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stefan Kasper-Virchow, Prof. Dr.
Facility Name
KHNW Frankfurt
City
Frankfurt
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thorsten Götze, PD Dr.
Facility Name
Markus-Krankenhaus Frankfurt
City
Frankfurt
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Claus Bolling, Dr.
Facility Name
Universitätsklinikum Frankfurt
City
Frankfurt
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christine Koch, Dr.
Facility Name
Universitätsklinikum Freiburg
City
Freiburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Quante, Prof. Dr.
Facility Name
Gemeinschaftspraxis internistische Onkologie Fürth
City
Fürth
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jochen Wilke, Dr.
Facility Name
Niels-Stensen Kliniken Georgsmarienhütte
City
Georgsmarienhütte
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jens Atzpodien, Prof. Dr.
Facility Name
Praxis Hämatologie Onkologie Gießen
City
Gießen
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Georg Schließer, Dr.
Facility Name
Universitätsmedizin Göttingen
City
Göttingen
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yong-Jun Peter Jo, Dr.
Facility Name
Universitätsklinikum Halle
City
Halle
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mascha Binder, Prof. Dr.
Facility Name
Universitätsklinikum Hamburg-Eppendorf
City
Hamburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marianne Sinn, PD Dr.
Facility Name
Medizinische Hochschule Hannover
City
Hannover
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Arndt Vogel, Prof. Dr.
Facility Name
St. Anna Hospital Herne
City
Herne
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vera Heuer, Dr.
Facility Name
Universitätsklinikum des Saarlandes
City
Homburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Matthias Glanemann, Prof. Dr.
Facility Name
Klinikum Ingolstadt GmbH
City
Ingolstadt
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Josef Menzel, Prof.
Facility Name
Universitätsklinikum Jena
City
Jena
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Udo Lindig, Dr.
Facility Name
Kliniken der Satdt Köln
City
Köln
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bernhard Sibbing, Dr.
Facility Name
Klinikum Landshut
City
Landshut
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christian Bogner, Dr.
Facility Name
VK&K Studien Landshut
City
Landshut
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Florian Kaiser, Dr.
Facility Name
Studienzentrum UnterEms Leer
City
Leer
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lothar Müller, Dr.
Facility Name
Universitätsklinikum Leipzig
City
Leipzig
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ulrich Hacker, Prof. Dr.
Facility Name
Klinikum Leverkusen
City
Leverkusen
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrea Heider, Dr.
Facility Name
Klinikum Lippe
City
Lippe
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christian Constantin, Dr.
Facility Name
Klinikum Ludwigsburg
City
Ludwigsburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stefan Angermeier, Dr.
Facility Name
Klinikum Magdeburg
City
Magdeburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christoph Kahl, Prof. Dr.
Facility Name
Universitätsmedizin Mainz
City
Mainz
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Markus Möhler, Prof. Dr.
Facility Name
OnkoNet Marburg GmbH
City
Marburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christina Balser, Dr.
Facility Name
Philipps-Universität Marburg
City
Marburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jorge Riera, Dr.
Facility Name
Johannes Wesling Klinikum Minden
City
Minden
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hans-Joachim Tischler, Dr.
Facility Name
Kliniken Maria Hilf Mönchengladbach
City
Mönchengladbach
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ullrich Graeven, Prof. Dr.
Facility Name
Klinikum der Universität München
City
München
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Voker Heinemann, Prof. Dr.
Facility Name
Klinikum rechts der Isar TU München
City
München
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sylvie Lorenzen, Prof. Dr.
Facility Name
München Klinik Bogenhausen
City
München
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin Fuchs, Dr.
Facility Name
München Klinik Neuperlach
City
München
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Meinolf Karthaus, Prof. Dr.
Facility Name
Gemeinschaftspraxis Münster
City
Münster
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christian Lerchenmüller, Dr.
Facility Name
Universitätsklinikum Münster
City
Münster
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Klaus Wethmar, Dr. Dr.
Facility Name
Friedrich-Ebert-Krankenhaus Neumünster
City
Neumünster
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Siegfried Haas, Dr.
Facility Name
Lukaskrankenhaus Neuss
City
Neuss
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ulf Reinhart, Dr.
Facility Name
Klinikum Nürnberg
City
Nürnberg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gabriele Siegler, Dr.
Facility Name
Pi.Tri-Studien GmbH Offenburg
City
Offenburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Caroline Schock, Dr.
Facility Name
Klinikum Passau
City
Passau
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas Südhoff, Prof. Dr.
Facility Name
Schwerpunktpraxis Penzberg
City
Penzberg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Sandherr, PD Dr.
Facility Name
Ernst von Bergmann Klinikum Potsdam
City
Potsdam
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Matthias Paland, Dr.
Facility Name
Studienzentrum Onkologie Ravensburg
City
Ravensburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tobias Dechow, Prof. Dr.
Facility Name
Krankenhaus Barmherzige Brüder Regensburg
City
Regensburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anke Schlenska-Lange, Dr.
Facility Name
Universitätsklinikum Regensburg
City
Regensburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hans Jürgen Schlitt, Prof. Dr.
Facility Name
Kreiskliniken Reutlingen
City
Reutlingen
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stefan Kubicka, Prof. Dr.
Facility Name
Mathias Spital Rheine
City
Rheine
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sebastian Bröckling, Dr.
Facility Name
RoMed Klinikum Rosenheim
City
Rosenheim
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gerhard Gerhard Puchtler, Dr.
Facility Name
Universitätsmedizin Rostock
City
Rostock
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Larissa Henze, Dr.
Facility Name
DIAK Klinikum Schwäbisch Hall
City
Schwäbisch Hall
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas Geer, Dr.
Facility Name
Marienkrankenhaus Siegen
City
Siegen
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ralph Naumann, Prof. Dr.
Facility Name
Klinikum Stuttgart
City
Stuttgart
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wolfram Bohle, Dr.
Facility Name
Marienhospital Stuttgart
City
Stuttgart
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Claudio Denzlinger, Prof. Dr.
Facility Name
Krankenhaus der Barmherzigen Brüder Trier
City
Trier
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Heinz Kirchen, Dr.
Facility Name
Universitätsklinikum Ulm
City
Ulm
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas J. Ettrich, Dr.
Facility Name
Klinikum Wetzlar
City
Wetzlar
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Birgitta Killing, Dr.
Facility Name
Onkologisches Zentrum Wolfsburg-Helmstedt
City
Wolfsburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas Gabrysiak, Dr.
Facility Name
Petrus-Krankenhaus Wuppertal
City
Wuppertal
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Matthias Sandmann, Dr.
Facility Name
Gemeinschaftspraxis Würzburg
City
Würzburg
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Björn Schöttker, Dr.

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
35366831
Citation
Raschzok N, Stintzing S, Heinemann V, Rauch G, Ricke J, Guckenberger M, Kurreck A, Alig AHS, Stahler A, Bullinger L, Schmelzle M, Schoning W, Lurje G, Krenzien F, Haase O, Rau B, Gebauer B, Sauer IM, Pratschke J, Modest DP. FIRE-9 - PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer. BMC Cancer. 2022 Apr 2;22(1):359. doi: 10.1186/s12885-022-09422-6.
Results Reference
derived

Learn more about this trial

Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)

We'll reach out to this number within 24 hrs